Apr 14, 2027Research
— / —No executable quote
Research candidateOpen
Zanzalintinib + atezolizumab
Exelixis · metastatic colorectal cancerMar 3, 2027 target
Will the FDA approve Zanzalintinib + atezolizumab for metastatic colorectal cancer?
EXEL-YES/ USDC
Outcome claim / Research candidate
Executable price
—
Change across observed prices in this windowImplied YES probability—Price-based, not a clinical forecast
Market not listed
No market price yet.
This program has no funded pool or observed trading history. Start with the evidence, or explore a clearly labeled scenario.
0 trading observationsNo live price feed
YES —NO —
This chart stays empty until observations exist. Research status is not an approval probability. A sandbox session creates a separate virtual price history.
Rx-EXEL-2703 / Evidence
UnlistedPool price—No deployed pool
Dated model P(YES)—No dated model artifact
Days to sponsor target121Date-only guidance
Source publishedSep 11, 2026
Research snapshotOct 28, 2026
FDA targetMar 3, 2027
Small moleculeNCT05425940
A pool price describes trading inventory; a model estimates an outcome. Neither a live price nor a dated forecast is available for this unlisted catalyst.
Program overview
Filing reports an extended review for zanzalintinib plus atezolizumab, with a March 3, 2027 target.
THERAPEUTIC AREAOncology
DRUG / PROGRAMZanzalintinib + atezolizumab
INDICATIONmetastatic colorectal cancer
REGULATORY TARGETMarch 3, 2027
Agent model / unavailable
No reviewed probability or reasoning artifact is available. A neutral pool opening is not a clinical base rate.
What matters
- Old December 3 2026 date is superseded; combination and treatment line must match final resolution text.
- Approval, the stock price and commercial success are different outcomes. A claim only pays on its specified event.
- Future program funding and tokenized financing require separate rights and contracts. An event claim gives no equity, royalty or drug IP.